Cargando…

Influence of YES1 Kinase and Tyrosine Phosphorylation on the Activity of OCT1

Organic cation transporter 1 (OCT1) is a transporter that regulates the hepatic uptake and subsequent elimination of diverse cationic compounds. Although OCT1 has been involved in drug-drug interactions and causes pharmacokinetic variability of many prescription drugs, details of the molecular mecha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Uddin, Muhammad Erfan, Garrison, Dominique A., Kim, Kyeongmin, Jin, Yan, Eisenmann, Eric D., Huang, Kevin M., Gibson, Alice A., Hu, Zeping, Sparreboom, Alex, Hu, Shuiying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8006202/ https://www.ncbi.nlm.nih.gov/pubmed/33790797 http://dx.doi.org/10.3389/fphar.2021.644342

Ejemplares similares

In Vitro and In Vivo Inhibition of MATE1 by Tyrosine Kinase Inhibitors
por: Uddin, Muhammad Erfan, et al.
Publicado: (2021)

Role of OATP1B1 and OATP1B3 in Drug-Drug Interactions Mediated by Tyrosine Kinase Inhibitors
por: Garrison, Dominique A., et al.
Publicado: (2020)

Itraconazole-Induced Increases in Gilteritinib Exposure Are Mediated by CYP3A and OATP1B
por: Garrison, Dominique A., et al.
Publicado: (2022)

Targeting OCT2 with Duloxetine to Prevent Oxaliplatin-induced Peripheral Neurotoxicity
por: Nepal, Mahesh R., et al.
Publicado: (2022)

Bioactive Phytoconstituents as Potent Inhibitors of Tyrosine-Protein Kinase Yes (YES1): Implications in Anticancer Therapeutics
por: Yang, Chunmin, et al.
Publicado: (2022)

Analysis of intracellular tyrosine phosphorylation in circulating neutrophils as a rapid assay for the in vivo effect of oral tyrosine kinase inhibitors
por: Futosi, Krisztina, et al.
Publicado: (2023)

Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro–in vivo correlations
por: Hu, S, et al.
Publicado: (2014)

Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlations
por: Hu, S, et al.
Publicado: (2017)

Yes-mediated phosphorylation of focal adhesion kinase at tyrosine 861 increases metastatic potential of prostate cancer cells
por: Chatterji, Tanushree, et al.
Publicado: (2015)

Tyrosine Phosphorylation of Botulinum Neurotoxin Protease Domains
por: Toth, Stephen, et al.
Publicado: (2012)

Expansion of Knowledge on OCT1 Variant Activity In Vitro and In Vivo Using Oct1/2(−/−) Mice
por: Morse, Bridget L., et al.
Publicado: (2021)

Role of equilibrative nucleoside transporter 1 (ENT1) in the disposition of cytarabine in mice
por: Anderson, Jason T., et al.
Publicado: (2019)

OCT1 Polyspecificity—Friend or Foe?
por: Meyer, Marleen J., et al.
Publicado: (2021)

MATE1 Deficiency Exacerbates Dofetilide-Induced Proarrhythmia
por: Uddin, Muhammad Erfan, et al.
Publicado: (2022)

A Metabolomics Approach for Predicting OATP1B-Type Transporter-Mediated Drug–Drug Interaction Liabilities
por: Li, Yang, et al.
Publicado: (2022)

Phosphorylation of Ack1 by the Receptor Tyrosine Kinase Mer
por: Hayashi, Samantha Y., et al.
Publicado: (2023)

Predicting individual-specific cardiotoxicity responses induced by tyrosine kinase inhibitors
por: Shim, Jaehee V., et al.
Publicado: (2023)

Inhibition of Spleen Tyrosine Kinase Restores Glucocorticoid Sensitivity to Improve Steroid-Resistant Asthma
por: Liu, Qian, et al.
Publicado: (2022)

Unraveling the Function of Lemur Tyrosine Kinase 2 Network
por: Cruz, Daniel F., et al.
Publicado: (2019)

Systemic Mastocytosis: Following the Tyrosine Kinase Inhibition Roadmap
por: Piris-Villaespesa, Miguel, et al.
Publicado: (2020)

Nuclear Dbf2-related Kinase 1 functions as tumor suppressor in glioblastoma by phosphorylation of Yes-associated protein
por: Chen, Bin, et al.
Publicado: (2021)

Interactions of antiretroviral drugs with the SLC22A1 (OCT1) drug transporter
por: Moss, Darren M., et al.
Publicado: (2015)

Intentional Modulation of Ibrutinib Pharmacokinetics through CYP3A Inhibition
por: Eisenmann, Eric D., et al.
Publicado: (2021)

Exploring pharmacokinetics of talazoparib in ABCB1/ABCG2-deficient mice using a novel UHPLC-MS/MS method
por: Talebi, Zahra, et al.
Publicado: (2023)

Specific Oncogenic Activity of the Src-Family Tyrosine Kinase c-Yes in Colon Carcinoma Cells
por: Sancier, Florence, et al.
Publicado: (2011)

Interaction of Antifungal Drugs with CYP3A- and OATP1B-Mediated Venetoclax Elimination
por: Eisenmann, Eric D., et al.
Publicado: (2022)

Model-Based Biomarker Selection for Dose Individualization of Tyrosine-Kinase Inhibitors
por: Centanni, Maddalena, et al.
Publicado: (2020)

Receptor Tyrosine Kinases and Their Signaling Pathways as Therapeutic Targets of Curcumin in Cancer
por: Sudhesh Dev, Sareshma, et al.
Publicado: (2021)

Eph-mediated tyrosine phosphorylation of citron kinase controls abscission
por: Jungas, Thomas, et al.
Publicado: (2016)

Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor-Associated Cardiotoxicity: A Recent Five-Year Pharmacovigilance Study
por: Liu, Yihan, et al.
Publicado: (2022)

Identification of potential inhibitors based on compound proposal contest: Tyrosine-protein kinase Yes as a target
por: Chiba, Shuntaro, et al.
Publicado: (2015)

Isobutyrylcarnitine as a Biomarker of OCT1 Activity and Interspecies Differences in its Membrane Transport
por: Jensen, Ole, et al.
Publicado: (2021)

Diverse distribution of tyrosine receptor kinase B isoforms in rat multiple tissues
por: OTANI, Kosuke, et al.
Publicado: (2017)

Hepatocellular Toxicity Associated with Tyrosine Kinase Inhibitors: Mitochondrial Damage and Inhibition of Glycolysis
por: Paech, Franziska, et al.
Publicado: (2017)

Src Tyrosine Kinase Inhibitors: New Perspectives on Their Immune, Antiviral, and Senotherapeutic Potential
por: Rivera-Torres, José, et al.
Publicado: (2019)

The Bruton’s Tyrosine Kinase Inhibitor Ibrutinib Impairs the Vascular Development of Zebrafish Larvae
por: Wang, Kun, et al.
Publicado: (2021)

Clinical updates on tyrosine kinase inhibitors in HER2-positive breast cancer
por: Singh, Desh Deepak, et al.
Publicado: (2022)

Icotinib derivatives as tyrosine kinase inhibitors with anti-esophageal squamous carcinoma activity
por: Chen, Xiaojie, et al.
Publicado: (2022)

Thiosemicarbazones and selected tyrosine kinase inhibitors synergize in pediatric solid tumors: NDRG1 upregulation and impaired prosurvival signaling in neuroblastoma cells
por: Krchniakova, Maria, et al.
Publicado: (2022)

HIV-1 downregulates the expression and phosphorylation of receptor tyrosine kinase by targeting the NF-κB pathway
por: Feng, Tingting, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_kghbthd261fapnspdu4mvelpkn